SCHEMBL30540617

SCHEMBL30540617

COC(=O)c1cc(CN2CCC[C@H](C)C2)c2c(ccn2COCC[Si](C)(C)C)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TERT O14746 1/20 0.35
▸ KDM4E B2RXH2 6/20 0.35
▸ ALDH1A1 P00352 4/20 0.35
▸ HPGD P15428 3/20 0.35
▸ GLA P06280 2/20 0.35
▸ GAA P10253 2/20 0.35
▸ TP53 P04637 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.35
▸ HRH3 Q9Y5N1 4/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ METTL3 Q86U44 1/20 0.34
▸ MAPT P10636 2/20 0.34
▸ KLKB1 P03952 1/20 0.34
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ CASP1 P29466 1/20 0.33
▸ CASP7 P55210 1/20 0.33
▸ LMNA P02545 2/20 0.33
▸ HRH4 Q9H3N8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30540679 0.92 KLKB1 (0.38) TERTKDM4EALDH1A1GAATP53
SCHEMBL30540488 0.91 GRM2 (0.37) TERTKDM4ETP53RXFP1MAPT
SCHEMBL30540610 0.85 KDM4E (0.36) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL31115338 0.85 KDM4E (0.36) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL30540589 0.84 KLKB1 (0.34) KLKB1
SCHEMBL31115342 0.84 GRM2 (0.35) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL30540464 0.84 KLKB1 (0.33) TERTKDM4EALDH1A1HPGDGLA
SCHEMBL30540583 0.84 GRM2 (0.35) KDM4EALDH1A1HPGDGLAGAA
SCHEMBL31115364 0.84 KLKB1 (0.33) TERTKDM4EALDH1A1HPGDGLA
SCHEMBL30577596 0.82 TERT (0.43) TERTKDM4EALDH1A1HPGDGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163047-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE, LTD. (KY) 2025-05-22 — — US disclosed
EP-4476219-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BeiGene, Ltd. (KY) 2024-12-18 — — EP disclosed
CN-118696043-A Heterocyclic compounds, compositions thereof and methods of treatment therewith 百济神州有限公司 2024-09-24 — — CN disclosed
WO-2023151636-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE , LTD. (KY) 2023-08-17 — — WO disclosed
WO-2023151641-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE , LTD. (KY) 2023-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163047-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH NFATC1, GZMB, IFNG TERT 408/4885KDM4E 996/4885ALDH1A1 1242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback